Tempus

Today we reported financial results for the quarter ended March 31, 2026. Read the full report here: tempus.co/4tY8kCc

We will host an Investor Day on Friday, May 29, 2026 at 8:00 a.m. CT / 9:00 a.m. ET, which will feature our leadership team and will include presentations from the our Diagnostics and Data & Applications organizations. Due to capacity constraints, in-person attendance at Tempus’ Investor Day is by invitation only. A live webcast of the event can be accessed through this link: edge.media-server.com/mmc/p/xtnkvqcb/

Research now available in the Lens Library demonstrates how patient demographics and tumor genetics are linked to MAIT cell infiltration, providing potentially critical context for their role in the tumor microenvironment. Access the full study here: tempus.co/4tE3ji9

Join leaders from Tempus and @bmsnews for a live discussion on how AI-driven platforms are creating a new paradigm for understanding and addressing health equity and spotlight on a real-world case study in #aNSCLC that leveraged the Tempus Next Pathways platform across 13 community-based health systems to construct a unified, longitudinal view of the patient journey and surface critical insights. Register now: tempus.co/4ths0ju

In the rapidly evolving oncology landscape, NCCN guidelines and FDA approvals often change after a patient’s initial genomic test. To bridge this gap, Refresh provides automatic updates to therapy options for patients when guidelines change or FDA-approved therapy options emerge without requiring an additional sample. This feature is available to all Hub users. Learn more: tempus.co/4ukW9zd

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, recently joined Tempus leaders to discuss how biotechs can leverage multimodal data to accelerate R&D and de-risk programs. A new article recaps their conversation, including the practical hurdles in bridging scientific ideas with actionable development plans. Read now: tempus.co/3QGo4ej

We are honored to be named one of @TIME “10 Most Influential Health and Life Science Companies of 2026.” Inclusion in this list is a testament to the rigorous work of our team and our clinical, research, and technology partners to bridge the gap between data and action at scale. Learn more: tempus.co/4vXX36m

Recently, @bmsnews utilized the Tempus Next Pathways program to address care gaps patients with advanced non-small cell lung cancer (aNSCLC). Deployed across 13 community-based health systems, the Tempus Next Pathways program provided a unified, longitudinal view of the patient journey, delivering actionable insights that helped close 41% of the biomarker testing care gap. Learn more about this work and how Tempus can help unlock insights and accelerate your programs here: tempus.co/3P7KDIn

Our latest article explores the path of Paige Prostate, the first-ever FDA marketing authorization for a software algorithm device to assist users in digital pathology in 2021, and its recent achievement of EU IVDR certification in 2025. The validation of Paige Prostate exemplifies how powerful AI applications can support the critical expertise of physicians to create a new standard of care. Read on: tempus.co/4cPEHM3

A critical opportunity in clinical research is to bridge the gap between the growing number of available trials and the patients who stand to benefit from them. As trial complexity increases, the traditional, manual approach to patient identification presents significant challenges to meeting this need. By automating patient identification, Tempus’ Next Trials platform can help accelerate accrual for active studies and unlock opportunities to advance research programs. Learn more in a new article here: tempus.co/4vL6aat #ACRP2026

Today we announced a multi-faceted collaboration with @KeckMedicineUSC and @KECKSchool_USC aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is built to drive clinical impact, research scale, and long-term innovation—transforming care delivery across more than 1.5 million annual patient visits to all USC-affiliated hospitals and clinics across Southern California. Learn more: tempus.co/3Qrk41e

Please join us in celebrating #MedicalLaboratoryProfessionalsWeek! While their work is often done behind the scenes, their impact is at the forefront of everything we do. Thank you to each member of our incredible lab team for their expertise, their tireless work, and for being the essential link in our mission to advance precision medicine.

We're looking forward to attending #ACRP2026 to share how our AI-powered technology supports faster trial activation, accurate patient matching, enhanced resource utilization, and a unified approach to help advance your research goals and accelerate clinical trial enrollment. Stop by Booth #716 to meet with our team and experience live demos of Next Trials. Find more information including live session details here: tempus.co/4t1y0Na @ACRPDC

🧬 New study from #ChaeLab @NorthwesternMed & @TempusAI analyzes RNA-seq data from 2,235 mNSCLC patients on 1st-line anti-PD-(L)1 + chemo 🔬 Using TIGIT, FOXP3, PD-L1 & TAM scores, unsupervised clustering revealed 4 distinct immune subtypes with very different survival outcomes 📊 The 4 clusters: 🏜️ Cluster 1 – Immune desert 🔄 Cluster 2 – TAM-enriched 🔥 Cluster 3 – Immune-hot 🧪 Cluster 4 – Myeloid-inflamed (PD-L1 high) 💡 Key takeaway: Tumor immune heterogeneity matters — one-size-fits-all IO may not be enough. Subtype-specific strategies could improve outcomes in #NSCLC @LurieCancer @NUFeinbergMed @NM_Lung @OncoAlert @IASLC

💡Insights from #AACR26 poster "Lauren subtype classification in gastric cancer using deep learning on real-world H&E images" The research team developed a deep learning classifier to automate Lauren subtype assignment in gastric cancer, addressing the inter-observer variability and scalability challenges of manual pathologist review. By analyzing de-identified H&E-stained images from 637 patient samples in the Tempus real-world database, the model achieved robust performance.

We will report financial results for the first quarter of 2026 on Tuesday, May 5, 2026 at 4:30 p.m. ET. Access the live webcast here: edge.media-server.com/mmc/p/rv7jv7ti/

Attend our upcoming live webinar to discover how #MRD data is shaping the cancer care continuum, with practical insights into its application in neoadjuvant, surgical, and surveillance settings. Our expert panelists: Peter A. Prieto, MD; Alan Tan, MD; and Luis E Raez, MD will share case-based examples and discuss the impact of MRD data on clinical decision-making. Register now: tempus.co/4tihLvU

Reminder to join us today, at 10:00 am – 11:00 am PST, for our #AACR26 Spotlight Theater. Kate Sasser, PhD, and Neil Bence, PhD, of @bmsnews are discussing how tethering deep molecular insights to high-velocity Lab-in-the-Loop screening helps de-risk clinical decisions and accelerate life-saving breakthroughs.

We're looking forward to kicking off @AACR in San Diego. Visit us at Booth #2337 to discover how our AI-enabled technologies and multimodal data are helping to advance precision medicine. Experience a live demonstration of Lens, our analytical tool designed to surface critical insights across multimodal data, and see how it is helping accelerate research and innovation. Learn more about Tempus at #AACR26 here: tempus.co/489i9Ev